[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-335173-105":59,"doc-detail-335173-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","improving-the-efficacy-of-cancer-immunotherapy-by-host-defence-caerin-11-and-19-peptides","Improving the efficacy of cancer immunotherapy by host-defence caerin 1.1 and 1.9 peptides","","Cancer remains a major global health challenge, and although immunotherapy has transformed cancer management, only a limited fraction of patients benefit. This restricted response is strongly linked to the immunosuppressive tumor microenvironment that reduces immunotherapy effectiveness. Naturally derived caerin 1 peptides, especially caerin 1.1 and caerin 1.9, show potent antitumor activity and can improve immunotherapy outcomes in animal models. This review synthesizes current evidence on how these peptides enhance immunotherapeutic efficacy, highlights underlying mechanisms, and addresses limitations and challenges.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/improving-the-efficacy-of-cancer-immunotherapy-by-host-defence-caerin-11-and-19-peptides/335173/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/improving-the-efficacy-of-cancer-immunotherapy-by-host-defence-caerin-11-and-19-peptides/335173.png","ImageObject",300,407,{"name":92,"@type":93},"Asher","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-11-13","2026-09-21",true,{"@type":102,"interactionType":103,"userInteractionCount":29},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"Why do only a limited number of patients respond to cancer immunotherapy?","Question",{"text":112,"@type":113},"Responses are limited largely due to an immunosuppressive tumor microenvironment that diminishes immunotherapy effectiveness.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"What roles do caerin 1.1 and caerin 1.9 play in cancer immunotherapy?",{"text":117,"@type":113},"They exhibit strong antitumor effects and enhance the efficacy of immunotherapies, particularly shown in animal models. The review focuses on their contribution to improved immunotherapeutic outcomes.",{"name":119,"@type":110,"acceptedAnswer":120},"Which factors influence the efficacy of cancer immunotherapy?",{"text":121,"@type":113},"Tumor factors such as tumor mutational burden, along with epigenetic changes in the tumor microenvironment and the patient’s microbiome, can positively or negatively affect immunotherapy outcomes.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},335173,1790913595,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":29,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":52,"language":139,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":140,"faqs":141,"seo_title":142,"seo_description":67,"update_tm":143,"read_time":144,"preview_page_count":4},687197207639,"https://ap-avatar.wpscdn.com/davatar_a8503ba1806abce46bf441b54a3ca4cd","MINI-REVIEW  \nImproving the efficacy of cancer immunotherapy by host-defence caerin 1.1 and 1.9 peptides  \nQuanlan Fua*, Yuandong Luoa*, Junjie Lib, Pingping Zhangc, Shuxian Tangc, Xinyi Songd, Jiawei Fud, Mengqi Liua, Rongmi Mod, Ming Weie, Hejie Lif, Xiaosong Liub,c,d, Tianfang Wangf, and Guoying Nib,c,d  \naMedical School of Guizhou University, Guiyang, Guizhou, China; bR&D Department, Zhongao Bio-pharmaceutical Technology Co., Ltd., Zhongshan, Guangdong Province, China; cCancer Research Institute, The First People’s Hospital of Foshan, Foshan, Guangdong, China; dThe First Affiliated Hospital/Clinical Medical School, Guangdong Pharmaceutical University, Guangzhou, Guangdong, China; eSchool of Medical Sciences, Griffith University, Gold Coast, QLD, Australia; fCentre for Bioinnovation, University of the Sunshine Coast, Maroochydore BC, QLD, Australia  \nABSTRACT  \nCancer remains a major global health challenge. Immunotherapy has revolutionized the management of cancer, yet only a limited number of patients respond to such treatments. This is largely attributed to the immunosuppressive tumor microenvironment, which diminishes the effectiveness of immunotherapy. Recent studies have underscored the potential of naturally derived caerin 1 peptides, particularly caerin 1.1 and caerin 1.9, which exhibit strong antitumor effects and enhance the efficacy of immunotherapies in animal models. This review encapsulates the current research aimed at augmenting the effectiveness of immunotherapy, focusing on the role of caerin 1.1 and caerin 1.9 in boosting immunotherapeutic outcomes, elucidating possible mechanisms, and discussing their limitations and challenges.  \nARTICLE HISTORY  \nReceived 5 March 2024 Revised 7 July 2024 Accepted 25 July 2024  \nKEYWORDS  \nCaerin 1 peptide; immune checkpoint blockade; therapeutic vaccine; tumor microenvironment; macrophage  \nIntroduction  \nCancer continues to be a major contributor to global mortality, presenting a significant public health challenge. 1 Unlike chemotherapy or radiotherapy, which can affect both cancerous and normal cells, cancer immunotherapy represents a revolutionary approach. It leverages the body’s immune system to specifically target and eliminate cancer cells, sparing normal cells and tissues.2,3 This strategy has transformed the field of cancer treatment,4,5 offering a beacon of hope for individuals battling various types of cancers.  \nOne of the most remarkable breakthroughs in cancer immunotherapy has been the advent of immune checkpoint blockade (ICB) . Immune checkpoints like Programmed cell death protein 1(PD-1), Cytotoxic T-lymphocyte-associated protein 4 (CTLA-4), play a crucial role in regulating immune responses and are often exploited by cancer cells to evade detection or attack by immune effector cells, such as T cells, NK cells and macrophages.6–8 Checkpoint inhibitors such aspembrolizumab and nivolumab have shown tremendous success across a variety of cancers, including melanoma, lung cancer, kidney cancer, and bladder cancer.9–11 These inhibitors work by blocking the checkpoint molecules, essentially reinvigorating the immune system’s ability to recognize and combat cancer cells.12  \nAnother promising avenue is Chimeric Antigen Receptor T-cell (CAR-T) therapy, which involves genetically modifying a patient’s own T cells to express CARs targeting specific cancerassociated antigens. CAR-T therapy has demonstrated efficacy,  \nparticularly in hematological malignancies, such as acute lymphoblastic leukemia and non-Hodgkin lymphoma.13, 14  \nConcurrently, cancer vaccines have gained renewed interest combating solid tumors. These vaccines are designed to stimulate the cellular immune system, particularly T cells, to identify and attack tumor cells. 15 The development of mRNAbased vaccines, exemplified by the success of COVID-19 vaccines, has driven innovation in cancer vaccine research. Personalized cancer vaccines, tailored to a patient’s unique tumor antigens known as ne","cbCaiixjmCKw4M6w","https://ap.wps.com/l/cbCaiixjmCKw4M6w","pdf",1510813,"English","# Introduction\n## Cancer immunotherapy and immune checkpoints\n## CAR-T therapy and cancer vaccines\n## Determinants of immunotherapy efficacy\n## Tumor microenvironment","[{\"question\":\"Why do only a limited number of patients respond to cancer immunotherapy?\",\"answer\":\"Responses are limited largely due to an immunosuppressive tumor microenvironment that diminishes immunotherapy effectiveness.\"},{\"question\":\"What roles do caerin 1.1 and caerin 1.9 play in cancer immunotherapy?\",\"answer\":\"They exhibit strong antitumor effects and enhance the efficacy of immunotherapies, particularly shown in animal models. The review focuses on their contribution to improved immunotherapeutic outcomes.\"},{\"question\":\"Which factors influence the efficacy of cancer immunotherapy?\",\"answer\":\"Tumor factors such as tumor mutational burden, along with epigenetic changes in the tumor microenvironment and the patient’s microbiome, can positively or negatively affect immunotherapy outcomes.\"}]","Improving the efficacy of cancer immunotherapy by host-defence caerin 1.1 and 1.9 peptides | PDF",1790009920,25]